Itonis Inc. Signs Licensing Agreement with MyECheck Inc. for Medical Marijuana Point of Purchase App

Investment Opinion

Share Tweet

Itonis Inc. Signs Licensing Agreement with MyECheck Inc. for Medical Marijuana Point of Purchase App

Itonis Inc. (OTC: ITNS) has signed a Licensing Agreement with MyECheck, Inc. that opens the gates for Itonis to possibly become a leading player in the blossoming medical marijuana industry. In the licensing agreement, Itonis will acquire a software license for MyECheck's patented mobile payment app that will facilitate point of purchase transactions for medical marijuana, gambling, and general retail sales. There is no expiration date on that license. The company believes there is a significant revenue opportunity in addressing the demand regarding medical marijuana and the point of sales from medical suppliers.

For more information on Itonis Inc. and the licensing agreement, visit:

Medbox, Inc. (OTC: MDBX) announced on March 26th that they have completed the requisite steps to formally become a fully-reporting company as of March 24, 2014 and is now subject to the Securities and Exchange Commission reporting requirements. The company is a leader in providing consulting services and patented medicine storage and dispensing systems to the medical and retail industries.

Fusion Pharm, Inc. (OTC: FSPM) has leased space in Seattle's SoDo warehouse district in anticipation of opening its first Washington State design and sales center later this spring. The company manufactures the PharmPods(TM) cultivation system. "The opening of our Seattle location marks an important milestone for FusionPharm as we begin to open sales centers in each new, major marketplace" commented FusionPharm CEO Scott Dittman.

Cannabis Science, Inc. (OTC: CBIS) announced recently that investors acquiring $500,000 of the recent private placement included Weedmaps Media Inc. (Weedmaps) and an Amsterdam-based investment company. Weedmaps Media is the world's largest online guide for medical cannabis patients. The full $1,000,000 private placement has been paid into the Company bank account. Cannabis Science specializes in cannabis formulation-based drug development and related consulting.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.